Department of Anaesthesia, Orthopaedic Hospital Orton, Helsinki, Finland.
Acta Anaesthesiol Scand. 2013 Aug;57(7):911-9. doi: 10.1111/aas.12107. Epub 2013 Mar 25.
Articaine and chloroprocaine have recently gained interest as short-acting spinal anaesthetics. Based on previous work comparing articaine 60 mg with chloroprocaine 40 mg, we hypothesised that articaine 40 mg and chloroprocaine 40 mg would produce similar spinal anaesthesa regarding block onset, maximal spread, and recovery.
In this randomised, double-blind study, adult patients (18-70 years, American Society of Anaesthesiologists physical status I-III, BMI < 36 kg/m(2) ) scheduled for day-case knee arthroscopy received either articaine 40 mg (20 mg/ml) (group A40, n = 16) or chloroprocaine 40 mg (20 mg/ml) (group C40, n = 18) intrathecally. Telephone interviews were performed on the first and seventh postoperative day to disclose possible side effects, e.g. transient neurological symptoms (TNS).
The groups were comparable regarding demographic data, onset and maximal spread of spinal anaesthesia, and duration of surgery. Surgery could be performed successfully under spinal anaesthesia except once in A40 (insufficient block) and once in C40 (prolonged surgery). Complete recovery was significantly slower in A40 vs. C40 for both motor block (105 (94/120) vs. 75 (71/90) min) [P < 0.001, Mann-Whitney U-test (MW-U)] and sensory block [135 (109/176) vs. 105 min (90/124)] (P < 0.02, MW-U), respectively [data are median (25th/75th percentiles)]. One patient from A40 showed mild TNS.
Both A40 and C40 provided mainly adequate spinal anaesthesia for day-case knee arthroscopy. While onset and maximal spread were comparable, the recovery from motor block was clearly faster with chloroprocaine after equivalent doses of spinal articaine and chloroprocaine.
阿替卡因和氯普鲁卡因作为短效椎管内麻醉剂最近引起了关注。基于之前比较阿替卡因 60mg 与氯普鲁卡因 40mg 的研究,我们假设阿替卡因 40mg 和氯普鲁卡因 40mg 在起效时间、最大扩散范围和恢复方面将产生类似的脊髓麻醉效果。
在这项随机、双盲研究中,接受日间膝关节镜检查的成年患者(18-70 岁,美国麻醉医师协会身体状况 I-III 级,BMI<36kg/m2)接受阿替卡因 40mg(20mg/ml)(A40 组,n=16)或氯普鲁卡因 40mg(20mg/ml)(C40 组,n=18)椎管内注射。在术后第 1 天和第 7 天进行电话访谈,以披露可能的副作用,例如短暂性神经症状(TNS)。
两组在人口统计学数据、脊髓麻醉的起效时间和最大扩散范围以及手术持续时间方面无差异。除 A40 组有一例(阻滞不足)和 C40 组有一例(手术时间延长)外,手术均能成功在脊髓麻醉下进行。A40 组的运动阻滞恢复时间明显慢于 C40 组,分别为 105(94/120)min 和 75(71/90)min(P<0.001,Mann-Whitney U 检验(MW-U))和感觉阻滞恢复时间[135(109/176)min 和 105min(90/124)](P<0.02,MW-U)[数据为中位数(25 分位/75 分位)]。A40 组有 1 例患者出现轻度 TNS。
A40 和 C40 均能为日间膝关节镜检查提供主要足够的脊髓麻醉。虽然起效时间和最大扩散范围相当,但在使用相同剂量的椎管内阿替卡因和氯普鲁卡因后,氯普鲁卡因的运动阻滞恢复明显更快。